Sanofi evolves its Executive Committee to support its next strategic chapter Paris, July 21, 2026. S

I identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics,

PARIS & LONDON--(BUSINESS WIRE)-- #DrugDiscovery--Aqemia, the drug invention company combining gener

All three can be bought on the dip.

Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as cri

FDA approves Sanofi’s Sarclisa Escena, the first subcutaneous multiple myeloma treatment administere

The US Food and Drug Administration (FDA) has approved subcutaneous (SC) Sarclisa (isatuximab-irfc)

Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered

The U.S. Food ​and Drug ‌Administration said on Friday ​it has ​approved Sanofi's blood ⁠cancer drug

Sino Biopharma expanded its GSK partnership in China and signed an AstraZeneca licensing deal worth

The European Commission said on Wednesday ​it would seek feedback ‌on commitments offered by French

Sanofi's phase III Baby-COMET study meets all goals for Nexviazyme in infantile-onset Pompe disease,

Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026. Sanofi announced

When dividend stocks drop in value, investors have the opportunity to secure some higher-than-typica

Sanofi says Nexviazyme met all Phase 3 trial endpoints in infantile Pompe disease, supporting a plan

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology c

Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3

EU opens antitrust probe into Sanofi over claims it disparaged rival flu vaccine Fluad in Germany an

The European Commission opened on Friday an ​investigation into whether French ‌drug giant Sanofi br

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 bill

Sanofi is reiterated as a compelling buy, trading at a pronounced valuation discount versus pharma p

Sanofi Foundation opens new chapter centered on future generations Paris, June 2 5 , 2026 . The Sano

Sanofi wins EU nod for Cenrifki in secondary progressive multiple sclerosis without relapses, while

Sanofi won European approval for Cenrifki in SPMS and secured Japan authorization for Wayrilz in chr

Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying

Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for s

The authorization of Cenrifki for the treatment of secondary progressive multiple sclerosis without

Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that

MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing in

SNY's Dupixent is expanding into new diseases and geographies, strengthening its position as a key d

AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its

Sanofi a ppoints  Paulo Fontoura   as   Global  Head of  R&D Paris ,  June 22 ,   2026. Sanofi today

Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read

Trump, in January, said "inflation has been defeated." Wall Street is now bracing for a 0.9%

Sanofi reports positive Phase 2 data for lunsekimig in asthma and nasal polyps, while atopic dermati

Medicare Chief Chris Klomp is optimistic for strong outcome in the search of CDC leader in midst of

A federal judge warns that RFK Jr.'s vaccine overhaul likely violates federal law. Discover the

Bloomberg

  Monday saw 825 companies set new 52-week lows.

  On Wednesday, 340 stocks hit new 52-week lows.

  Companies Reporting Before The Bell • PG&E (NYSE:PCG) is likely to report quarterly earnings

Stocks That Hit 52-Week Lows On Monday

3 ADR ETFs Your Broker Forgot to Mention